Radiation plus immunotherapy vs immunotherapy alone for NSCLC brain mets
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests if adding targeted radiation to a combination of immunotherapy (Ivonescimab) and chemotherapy works better than the drugs alone for people with non-small cell lung cancer (NSCLC) that has spread to the brain. It is for patients who have not had prior treatment for their advanced lung cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older.
- You must have NSCLC that has spread to the brain (1 to 10 new brain tumors).
- You must not have had prior radiation or systemic treatment for metastatic lung cancer.
- You can have mild symptoms controlled by a low dose of steroids (4 mg or less of dexamethasone per day).
- Your largest brain tumor must be less than 30 mm in longest diameter and less than 10 mL in volume, and total brain tumor volume less than 30 mL.
- You must not have certain serious medical conditions, like active autoimmune disease, uncontrolled high blood pressure, or a history of bleeding problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of a new immunotherapy drug (ivonescimab), standard chemotherapy, and focused radiation (stereotactic radiosurgery) for non-small cell lung cancer that has spread to the brain. The goal is to see if this combination can shrink tumors in both the lungs and brain.
This Phase 2 trial studies whether giving immunotherapy along with a precise form of brain radiation can control brain metastases from non-small cell lung cancer. It may help by shrinking or stabilizing spots in the brain while your body’s immune system is also activated.
This trial tests a combination of a targeted immunotherapy drug (cadonilimab) with a precise type of radiation to treat brain tumors that have grown after initial lung cancer treatment. The goal is to see if this approach can safely shrink brain metastases and improve outcomes.
This trial tests whether starting focused radiation to brain spots early (called SRS) along with osimertinib works better than taking osimertinib alone. It is for people with lung cancer that has an EGFR mutation and has not yet caused major brain symptoms.
This trial tests a new immunotherapy drug called ivonescimab combined with focused radiation therapy (SBRT) for patients with early-stage non-small cell lung cancer who cannot or prefer not to have surgery. The goal is to see if this combination can effectively treat the cancer while being tolerable.
This Phase 3 study tests whether immunotherapy or targeted medicine, with or without a one-time focused brain radiation procedure, can control brain metastases from melanoma or non-small cell lung cancer. It mainly enrolls people who have no (or minimal) brain symptoms and are newly diagnosed in the brain (except for certain recent brain surgery).
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.